James M Daly
CIK 1560782 · EVP, Chief Commercial Officer · last filed 2026-10-20
James M Daly is an EVP, Chief Commercial Officer who has filed 83 SEC Form 4 insider transactions across 8 companies since 2012. The most recent filing shows the insider was granted $12.5K of CYTK on Oct 20, 2026. Across all open-market trades the lifetime net is −$41.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions. 20 SEC filings were submitted jointly with INCYTE CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INCY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
RTE 141 & HENRY CLAY RD. BLDG E336
WILMINGTON, DE 19880
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CYTK | Director | 3,585 | $55.40 | $198.6K | $0 | 6 | 2026-10-20 |
| HALO | Director | 1,169 | $103.03 | $120.4K | $0 | 1 | 2026-10-02 |
| MDGL | Director | 3,081 | $430.77 | $1.33M | -$13.59M | 10 | 2026-06-18 |
| ACAD | Director | 12,148 | $18.90 | $229.6K | -$3.15M | 16 | 2026-06-01 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Director | 20,503 | — | — | -$2.29M | 11 | 2023-08-15 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Director | 109,873 | $0.07 | $8.2K | $0 | 13 | 2023-01-05 |
| CHIMERIX INC (CMRX) Delisted | Director | — | $8.54 | — | $0 | 5 | 2019-06-24 |
| INCY | EVP, Chief Commercial Officer | 3,521 | $121.77 | $428.8K | -$22.72M | 16 | 2015-06-25 |
Recent Filings
83 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-20 | CYTK | Grant (A) | +195 | $12.5K | EDGAR |
| 2026-10-02 | HALO | Grant (A) | +1,169 | $0 | EDGAR |
| 2026-07-16 | CYTK | Grant (A) | +151 | $12.5K | EDGAR |
| 2026-06-18 | MDGL | Grant (A) | +454 | $0 | EDGAR |
| 2026-06-01 | ACAD | Mixed | +8,107 | $0 | EDGAR |
| 2026-05-27 | CYTK | Grant (A) | +2,851 | $0 | EDGAR |
| 2026-04-15 | CYTK | Grant (A) | +191 | $12.5K | EDGAR |
| 2026-01-20 | CYTK | Grant (A) | +197 | $12.5K | EDGAR |
| 2025-11-12 | ACAD | Sell (S) | −30,000 | -$671.0K | EDGAR |
| 2025-11-10 | ACAD | Notice (144) | −30,000 | -$671.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.